Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018


Published on

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more at-

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  1. 1. Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  2. 2. Introduction to Report  Launch Date: June 30, 2014  Number of Pages: 153  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 5,995 Price For Site License: USD 11,990 Price For Global User License: USD 17,985 Delivery Time: Within 24 Hours (During Working Days)
  3. 3. About the Report Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled proliferation of B lymphocytes (a type of white blood cell) in the bone marrow, blood and lymphoid tissues. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the CLL market with coverage of both the first-line and relapsed/refractory settings. While the current standard of care consists of chemoimmunotherapy, CLL disease management is poised for dramatic changes, particularly in the treatment of relapsed/refractory and elderly patients, as four new drugs (Gazyva, Imbruvica, idelalisib and IPI-145) will launch during the forecast period.
  4. 4. Scope: Key countries covered: US, France, Germany, Italy, Spain, and UK Overview of CLL, including epidemiology, etiology, pathophysiology, clinical staging, symptoms, quality of life, and disease management. Topline CLL therapeutics market revenue from 2013-2018. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included. Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the CLL market.
  5. 5. Scope: Continues… Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early- stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available. Analysis of the current and future market competition in the 6MM CLL therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  6. 6. Reasons to buy: Develop and design your in-licensing and out- licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 6MM CLL market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 6MM CLL therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  7. 7. Key Findings: The CLL market, in the 6MM is forecasted to rapidly increase from $1.4bn in 2013 to $3.3bn in 2018, at a CAGR of 18.8%. This growth will be driven by the launch and adoption of four new premium-priced drugs during the forecast period, including Gazyva, Imbruvica, idelalisib and IPI-145. Publisher expects there will be rapid uptake of the new agents in the relapsed/refractory setting, particularly in those patients who do not have a good response to first-line treatment. Among the new agents, Publisher expects Imbruvica and idelalisib will dominate patient share and will account for more than 60% of all total sales in 2018 and drive 100% of total market growth.
  8. 8. Report Coverage 1. Introduction 2. Disease Overview 3. Disease Management 4. Epidemiology 5. Current Treatment Options 6. Unmet Needs Assessment and Oppportunity Analysis 7. R&D Strategies 8. Pipeline Assessment 9. Pipeline Valuation Analysis 10.Appendix For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  9. 9. Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @
  10. 10. How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : Phone: +1 302-703-7787 (USA) +91-8762746600 (India)